Scroll to READ
Radioligand therapy may provide hope for patients with advanced prostate cancer
Subheading style here
For the millions of men living with prostate cancer, finding appropriate treatments can improve the chances of a successful outcome. Prostate cancer is the second most diagnosed cancer in the United States, with 288,300 estimated new cases in 2023. In fact, the American Cancer Society estimates 1 in 8 men will be diagnosed with prostate cancer during their lifetime. The risk of prostate cancer in the United States is nearly 4 times greater than in the rest of the world.
The 5-year survival rate for men with localized prostate cancer is almost 100%. However, for men diagnosed with advanced prostate cancer, the 5-year survival rate is only 28%. For this reason, there is need for more research and treatment options. Novartis takes this mission very seriously and has dedicated teams working on a treatment approach known as radioligand therapy (RLT). RLT is a form of targeted nuclear medicine that may be able to identify and treat the disease where the cancer has metastasized (spread to other parts of the body) and is resistant to other treatments. RLT delivers radiation to cancer cells expressing a specific target, in prostate cancer, known as PSMA (prostate-specific membrane antigen), even when they have spread throughout the body. With RLT, the goal is to deliver the treatment to the target cells to damage or destroy those cells while limiting impact to surrounding cells.
Adolescents 12 to 17
years of age
Adults 18 to 65
years of age
If your doctor determines your prostate cancer is PSMA positive, you may be a candidate for PLUVICTO, which is the first and only RLT approved for patients with mCRPC who have undergone other anticancer therapies (androgen receptor pathway inhibitors and taxane-based chemotherapy). In a clinical study, eligible patients treated with PLUVICTO plus best standard of care (BSOC) lived longer without their cancer growing or spreading—a median of 8.7 months as compared with 3.4 months when only on BSOC.
Know your body
Be an advocate for yourself and other women
For the millions of men living with prostate cancer, finding appropriate treatments can improve the chances of a successful outcome. Prostate cancer is the second most diagnosed cancer in the United States, with 288,300 estimated new cases in 2023. In fact, the American Cancer Society estimates 1 in 8 men will be diagnosed with prostate cancer during their lifetime. The risk of prostate cancer in the United States is nearly 4 times greater than in the rest of the world.
The 5-year survival rate for men with localized prostate cancer is almost 100%. However, for men diagnosed with advanced prostate cancer, the 5-year survival rate is only 28%. For this reason, there is need for more research and treatment options. Novartis takes this mission very seriously and has dedicated teams working on a
Recognizing and voicing below the belt symptoms may help end the stigma around endometrial cancer.
Visit Qelbree.com for More Information
Visit SpotHerforEC.com for Resources
Content Sponsored by Novartis
Researchers at Novartis are continuing to explore the potential of RLTs, with the goal of providing innovative treatments to treat a myriad of cancers. By reimagining medicine, Novartis strives to deliver cutting-edge treatments to the patients who need them most. To learn more about PLUVICTO, visit www.Pluvicto.com.
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
National Cancer Institute. Cancer Stat Facts: Common Cancer Sites. Accessed October 23, 2023. https://seer.cancer.gov/statfacts/html/common.html#:~:text=Prostate%20cancer%20is%20the%20
leading,overall%20with%20288%2C300%20expected%20cases.
National Cancer Institute. Cancer Stat Facts: Prostate Cancer. Accessed October 23, 2023. https://seer.cancer.gov/statfacts/html/prost.html
American Cancer Society. Key Statistics for Prostate Cancer. Accessed October 23, 2023. https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html#:~:text=About%201%20man%20in%208,in%20non%2DHispanic%20Black%20men.
Barsouk A, Padala SA, Vakiti A, et al. Epidemiology, staging and management of prostate cancer. Med Sci (Basel). 2020;8(3):2-5. doi:10.3390/medsci8030028
National Cancer Institute. Surveillance, Epidemiology, and End Results program. Accessed October 23, 2023. http://seer.cancer.gov/statfacts/html/prost.html
Johns Hopkins Medicine. Prostate Cancer Prognosis. Accessed October 23, 2023. https://www.hopkinsmedicine.org/health/conditions-and-diseases/prostate-cancer/prostate-cancer-prognosis
Society of Nuclear Medicine and Molecular Imaging. Radiopharmaceutical therapy and prostate cancer. Accessed October 23, 2023. https://www.snmmi.org/AboutSNMMI/Content.aspx?ItemNumber=12772
Hope TA, Aggarwal R, Chee B, et al. Impact of a specific PSMA PET imaging on management in patients with biochemically recurrent prostate cancer. J Nucl Med. 2017;58(12):1956-1961.
Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy: a prospective randomised, multi-centre study. Lancet. 2020;395:1208-1216.
Sonni I, Eiber M, Fendler WP, et al. Impact of 68Ga-PSMA-11 PET/CT on staging and management of prostate cancer patients in various clinical settings: a prospective single-center study. J Nucl Med. 2020;61:1153-1160. doi:10.2967/jnumed.119.237602
Pluvicto. Prescribing information. Advanced Accelerator Applications USA, Inc.
Sartor O, J de Bono KN, Chi K, et al. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med, 2021;385(12):1091.
Please revisit on a desktop device!
This experience is not yet optimized for your mobile screen.
Concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range
The 5-year survival for men with localized prostate cancer is almost 100%. However, for men diagnosed with advanced prostate cancer, the 5-year survival rate is only 28%.
"
Found in more than 80% of men with mCRPC, PSMA is located on the surface of cancerous prostate cells.
"
1,2
3
4
5
7
13
Sponsored by Novartis Pharmaceuticals Corporation
What is PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)?
PLUVICTO is a radiopharmaceutical used to treat adults with an advanced cancer called prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that:
has spread to other parts of the body (metastatic), and
has already been treated with other anticancer treatments
IMPORTANT SAFETY INFORMATION
What is the most important information I should know about PLUVICTO?
Use of PLUVICTO involves exposure to radioactivity. Long-term, accruing radiation exposure is associated with an increased risk for cancer.
To minimize radiation exposure to others following administration of PLUVICTO, limit close contact (less than 3 feet) with household contacts for 2 days or with children and pregnant women for 7 days, refrain from sexual activity for 7 days, and sleep in a separate bedroom from household contacts for 3 days, from children for 7 days, or from pregnant women for 15 days.
PLUVICTO may cause serious side effects, including:
Low level of blood cell counts. Tell your doctor right away if you develop any new or worsening symptoms, including:
Tiredness or weakness
Pale skin
Shortness of breath
Bleeding or bruising more easily than normal or difficulty stopping bleeding
Frequent infections with signs such as fever, chills, sore throat, or mouth ulcers
Kidney problems. Tell your doctor right away if you develop any new or worsening symptoms, including passing urine less often or passing much smaller amounts of urine than usual
Before you receive PLUVICTO, tell your doctor if any of these apply to you:
Before administration of PLUVICTO, you should drink plenty of water in order to urinate as often as possible during the first hours after administration.
The most common side effects of PLUVICTO include:
Tiredness
Dry mouth
Nausea
Low red blood cell count
Loss of appetite
Changes in bowel movements (constipation or diarrhea)
Vomiting
Low blood platelet count
Urinary tract infection
Weight loss
Abdominal pain
These are not all of the possible side effects of PLUVICTO. Call your doctor for advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please see full Prescribing Information.
®
REFERENCES
You have low level of blood cell counts (hemoglobin, white blood cell count, absolute neutrophil count, platelet count)
You have or have had tiredness, weakness, pale skin, shortness of breath, bleeding or bruising more easily than normal or difficulty stopping bleeding, or frequent infections with signs such as fever, chills, sore throat, or mouth ulcers (possible signs of myelosuppression)
You have or have had kidney problems
You have or have had any other type of cancer or treatment for cancer, as PLUVICTO contributes to your long-term cumulative radiation exposure
You are sexually active as:
All radiopharmaceuticals, including PLUVICTO, have the potential to cause harm to an unborn baby
You should use effective contraception for intercourse during treatment with PLUVICTO and for 14 weeks after your last dose
PLUVICTO may cause temporary or permanent infertility
treatment approach known as radioligand therapy (RLT). RLT is a form of targeted nuclear medicine that may be able to identify and treat the disease where the cancer has metastasized (spread to other parts of the body) and is resistant to other treatments. RLT delivers radiation to cancer cells expressing a specific target, in prostate cancer, known as PSMA (prostate-specific membrane antigen), even when they have spread throughout the body. With RLT, the goal is to deliver the treatment to the target cells to damage or destroy those cells while limiting impact to surrounding cells.
For patients with mCRPC (metastatic castration-resistant prostate cancer), there is a molecular imaging test that can detect the biomarker called PSMA. Found in more than 80% of men with mCRPC, PSMA is located on the surface of cancerous prostate cells. The PSMA biomarker is detected using PET (positron emission tomography) scans that allow doctors to detect and identify PSMA-positive cancer cells. These scans help doctors to see whether the cancer has spread throughout the body and, if it has, where it has spread–so they can see it and treat it.
288k
cases
Prostate cancer is the second most diagnosed cancer in the United States, with 288,300 estimated new cases in 2023.
1 in 8
men
In fact, the American Cancer Society estimates 1 in 8 men will be diagnosed with prostate cancer during their lifetime.
4x
greater
The risk of prostate cancer in the United States is nearly 4 times greater than in the rest of the world.
What SHE didn't know
100%
The five-year survival rate for men with local prostate cancer is almost 100%. However, men diagnosed with advanced prostate cancer have a five-year survival rate of only 30%.
By reimagining medicine, Novartis strives to deliver cutting-edge treatments to the patients who need them most.
To learn more about PLUVICTO, visit Pluvicto.com
1,2
3
4
6
8-10
12
Not an actual doctor
If your doctor determines your prostate cancer is PSMA positive, you may be a candidate for PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan), which is the first and only RLT approved for mCRPC patients who have undergone other anticancer therapies without success, like androgen receptor pathwiay inhibitors and taxane-based chemotherapy. By attaching to PSMA and releasing radiation to kill cancerous tumor cells, PLUVICTO has proven to be a promising therapy for people with advanced prostate cancer. In a clinical study, men treated with PLUVICTO plus best standard of care (BSoC) lived longer without their cancer growing or spreading—a median of 8.7 months compared to 3.4 months when only on BSoC.
For patients with mCRPC (metastatic castration-resistant prostate cancer), there is a molecular imaging test that can detect the biomarker called PSMA. Found in more than 80% of men with mCRPC, PSMA is located on the surface of cancerous prostate cells. The PSMA biomarker is detected using PET (positron emission tomography) scans that allow doctors to detect and identify PSMA-positive cancer cells. These scans help doctors to see whether the cancer has spread throughout the body and, if it has, where it has spread–so they can see it and treat it.
If your doctor determines your prostate cancer is PSMA positive, you may be a candidate for PLUVICTO, which is the first and only RLT approved for patients with mCRPC who have undergone other anticancer therapies (androgen receptor pathway inhibitors and taxane-based chemotherapy). In a clinical study, eligible patients treated with PLUVICTO plus best standard of care (BSOC) lived longer without their cancer growing or spreading—a median of 8.7 months as compared with 3.4 months when only on BSOC.
Researchers at Novartis are continuing to explore the potential of RLTs, with the goal of providing innovative treatments to treat a myriad of cancers. By reimagining medicine, Novartis strives to deliver cutting-edge treatments to the patients who need them most. To learn more about PLUVICTO, visit www.Pluvicto.com.
®
3
What is PLUVICTO (lutetium Lu 177 vipivotide
tetraxetan)?
PLUVICTO is a radiopharmaceutical used to treat adults with
an advanced cancer called prostate-specific membrane
antigen–positive metastatic castration-resistant prostate
cancer (PSMA-positive mCRPC) that:
has spread to other parts of the body (metastatic), and
has already been treated with other anticancer treatments
IMPORTANT SAFETY INFORMATION
What is the most important information I should know
about PLUVICTO?
Use of PLUVICTO involves exposure to radioactivity. Long-
term, accruing radiation exposure is associated with an
increased risk for cancer.
To minimize radiation exposure to others following
administration of PLUVICTO, limit close contact (less than 3
feet) with household contacts for 2 days or with children and
pregnant women for 7 days, refrain from sexual activity for 7
days, and sleep in a separate bedroom from household
contacts for 3 days, from children for 7 days, or from
pregnant women for 15 days.
PLUVICTO may cause serious side effects, including:
Low level of blood cell counts. Tell your doctor right
away if you develop any new or worsening symptoms,
including:
Tiredness or weakness
Pale skin
Shortness of breath
Bleeding or bruising more easily than normal or difficulty
stopping bleeding
Frequent infections with signs such as fever, chills,
sore throat, or mouth ulcers
Kidney problems. Tell your doctor right away if you
develop any new or worsening symptoms, including passing
urine less often or passing much smaller amounts of urine
than usual
Before you receive PLUVICTO, tell your doctor if any
of these apply to you:
Before administration of PLUVICTO, you should drink
plenty of water in order to urinate as often as possible during
the first hours after administration.
The most common side effects of PLUVICTO include:
Tiredness
Dry mouth
Nausea
Low red blood cell count
Loss of appetite
Changes in bowel movements (constipation or diarrhea)
Vomiting
Low blood platelet count
Urinary tract infection
Weight loss
Abdominal pain
These are not all of the possible side effects of PLUVICTO.
Call your doctor for advice about side effects. You are
encouraged to report negative side effects of prescription
drugs to the FDA. Visit www.fda.gov/medwatch, or call
1-800-FDA-1088.
Please see full Prescribing Information.
You have low level of blood cell counts (hemoglobin,
white blood cell count, absolute neutrophil count,
platelet count)
You have or have had tiredness, weakness, pale skin,
shortness of breath, bleeding or bruising more easily
than normal or difficulty stopping bleeding, or frequent
infections with signs such as fever, chills, sore throat, or
mouth ulcers (possible signs of myelosuppression)
You have or have had kidney problems
You have or have had any other type of cancer or
treatment for cancer, as PLUVICTO contributes to your
long-term cumulative radiation exposure
You are sexually active as:
All radiopharmaceuticals, including PLUVICTO, have
the potential to cause harm to an unborn baby
You should use effective contraception for intercourse
during treatment with PLUVICTO and for 14 weeks
after your last dose
PLUVICTO may cause temporary or permanent infertility
®
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
National Cancer Institute. Cancer Stat Facts: Common Cancer Sites. Accessed October 23, 2023. https://seer.cancer.gov/statfacts/html/common.html#:~:
text=Prostate%20cancer%20is%20the%20
leading,overall%20with%20288%2C300%20expected
%20cases.
National Cancer Institute. Cancer Stat Facts: Prostate Cancer. Accessed October 23, 2023. https://seer.cancer.gov/statfacts/html/prost.html
American Cancer Society. Key Statistics for Prostate Cancer. Accessed October 23, 2023. https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html#:~:text=About%201%20man%20in%208
,in%20non%2DHispanic%20Black%20men.
Barsouk A, Padala SA, Vakiti A, et al. Epidemiology, staging and management of prostate cancer. Med Sci (Basel). 2020;8(3):2-5. doi:10.3390/medsci8030028
National Cancer Institute. Surveillance, Epidemiology, and End Results program. Accessed October 23, 2023. http://seer.cancer.gov/statfacts/html/prost.html
Johns Hopkins Medicine. Prostate Cancer Prognosis. Accessed October 23, 2023. https://www.hopkinsmedicine.org/health/conditions-and-diseases/prostate-cancer/prostate-cancer-prognosis
Society of Nuclear Medicine and Molecular Imaging. Radiopharmaceutical therapy and prostate cancer. Accessed October 23, 2023. https://www.snmmi.org/AboutSNMMI/Content.aspx?It
emNumber=12772
Hope TA, Aggarwal R, Chee B, et al. Impact of a specific PSMA PET imaging on management in patients with biochemically recurrent prostate cancer. J Nucl Med. 2017;58(12):1956-1961.
Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy: a prospective randomised, multi-centre study. Lancet. 2020;395:1208-1216.
Sonni I, Eiber M, Fendler WP, et al. Impact of 68Ga-PSMA-11 PET/CT on staging and management of prostate cancer patients in various clinical settings: a prospective single-center study. J Nucl Med. 2020;61:1153-1160. doi:10.2967/jnumed.119.237602
Pluvicto. Prescribing information. Advanced Accelerator Applications USA, Inc.
Sartor O, J de Bono KN, Chi K, et al. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med, 2021;385(12):1091.
REFERENCES
11